Literature DB >> 7557947

Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.

L Buø1, G I Meling, T S Karlsrud, H T Johansen, A O Aasen.   

Abstract

The distributions of urokinase and tissue plasminogen activators (uPA, tPA), uPA receptor (uPAR), and plasminogen activator inhibitors (PAI-1, PAI-2) were studied immunohistochemically in two subsets of colorectal adenocarcinomas with low and high aggressiveness, respectively: nine Dukes' stage A tumors with additional other good prognostic markers and 13 Duke's stage C tumors with also other poor prognostic markers (referred to as Dukes' stage A and Dukes' stage C tumors). The results showed that these components of the tissue destructive plasminogen activation system were accumulated at the invading front of the tumors. Both tumor groups showed accumulations of uPA, uPAR, and PAI-1 at the tumor-host interface compared with the location within the tumor epithelium and the adjacent normal mucosa and muscularis propria (all P < .05). However, the uPA level at the tumor-host interface in the Dukes' stage C tumors was twice the level in the Dukes' stage A tumors (P < .05). The uPAR level was also significantly higher in the Dukes' stage C tumors (P < .05), whereas the PAI-1 level was not significantly higher. This may indicate that uPA in more aggressive tumors exceeds the inhibitory capacity represented by PAIs, resulting in enhanced tissue destructive potential that promotes tumor invasion. uPA and uPAR antigen levels and the uPA/PAI-1 ratio at the tumor-host interface appeared to be related to tumor aggressiveness in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557947     DOI: 10.1016/0046-8177(95)90276-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.

Authors:  Matthias Steinert; Manja Wobus; Carsten Boltze; Alexander Schütz; Mandy Wahlbuhl; Jörg Hamann; Gabriela Aust
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.

Authors:  Neelesh Sharma; Maher Saifo; Ila R Tamaskar; Ramkumar Bhuvaneswari; Terry Mashtare; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2010-12

3.  Proteolysis in colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Mol Pathol       Date:  1999-06

4.  Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.

Authors:  E A Baker; F G Bergin; D J Leaper
Journal:  Mol Pathol       Date:  2000-12

5.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Authors:  H Allgayer; R Babic; K U Grützner; B C Beyer; A Tarabichi; F W Schildberg; M M Heiss
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

Review 6.  Beta-catenin--a linchpin in colorectal carcinogenesis?

Authors:  Newton Alexander Chiang Shuek Wong; Massimo Pignatelli
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

7.  Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization.

Authors:  S R Harvey; S N Sait; Y Xu; J L Bailey; R M Penetrante; G Markus
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

8.  Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Authors:  Lisa Pleyer; Philip Went; Gudrun Russ; Erika Prinz; Viktoria Faber; Hans-Joachim Röwert; Renate Karlbauer; Richard Greil
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Proteolysis in human breast and colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Association between KRAS mutation and lung metastasis in advanced colorectal cancer.

Authors:  A A L Pereira; J F M Rego; V Morris; M J Overman; C Eng; C R Garrett; A T Boutin; R Ferrarotto; M Lee; Z-Q Jiang; P M Hoff; J-N Vauthey; E Vilar; D Maru; S Kopetz
Journal:  Br J Cancer       Date:  2014-12-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.